Pictet Asset Management’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.72M Sell
207,256
-11,793
-5% -$309K 0.01% 730
2026
Q1
$4.36M Sell
219,049
-10,178
-4% -$203K ﹤0.01% 801
2025
Q4
$3.7M Sell
229,227
-8,676
-4% -$131K ﹤0.01% 834
2025
Q3
$2.7M Buy
237,903
+225,231
+1,777% +$2.94M ﹤0.01% 844
2025
Q2
$147K Hold
12,672
– – ﹤0.01% 1887
2025
Q1
$111K Hold
12,672
– – ﹤0.01% 1915
2024
Q4
$182K Hold
12,672
– – ﹤0.01% 1874
2024
Q3
$286K Buy
12,672
+2,130
+20% +$44K ﹤0.01% 1634
2024
Q2
$205K Sell
10,542
-306
-3% -$8.01K ﹤0.01% 1752
2024
Q1
$407K Buy
10,848
+306
+3% +$13.4K ﹤0.01% 1393
2023
Q4
$590K Hold
10,542
– – ﹤0.01% 1180
2023
Q3
$435K Buy
+10,542
New +$548K ﹤0.01% 1296

Other funds holding TXG

Pictet Asset Management's TXG Position: Q2 2026 in Review

Pictet Asset Management reduced its 10x Genomics (TXG) stake by 5.4% in Q2 2026, selling an estimated $309K and leaving 207,256 shares worth $7.72M. The position accounts for 0.01% of the portfolio, ranked #730.

Pictet Asset Management first reported a position in TXG in Q3 2023 and has held it in 12 quarters since. 393 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Pictet Asset Management held 207,256 shares of 10x Genomics worth $7.72M as of Q2 2026.
  • Pictet Asset Management sold 11,793 10x Genomics shares in Q2 2026, an estimated $309K.
  • 10x Genomics made up 0.01% of Pictet Asset Management's portfolio in Q2 2026, its #730 holding.
  • Pictet Asset Management first reported a position in 10x Genomics in Q3 2023 and has held it in 12 quarters since.
  • 393 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.